Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Cisapride in cats and dogs: regulatory status, dosing, and cardiac safety
Cisapride has the broadest prokinetic reach of the drugs in common use, which is why it anchors medical management of feline constipation and early megacolon. It is also an unapproved, compounded-only drug with no controlled clinical trial in cats, a fifteenfold spread across published dose recommendations, and a hERG-mediated cardiac liability characterised in cats and dogs only at grossly supratherapeutic doses. This hub separates trial evidence from expert recommendation, quotes every dose figure from the source that printed it, and sets out where cisapride stops working — a failure of enteric nerves, not of muscle — and surgery begins.
Read →Sucralfate in Dogs and Cats: Dosing, Timing, and What the Evidence Supports
Sucralfate is a locally acting mucosal barrier agent that needs acid to work, not an acid suppressant. What the 2018 ACVIM consensus actually recommends, the PPI co-administration question, the quantified 2-hour drug-separation data in dogs, and dosing for both species.
Read →Metronidazole in Dogs and Cats: A Clinical Evidence Review
A clinical reference on metronidazole in dogs and cats: mechanism and spectrum, the randomised trials on acute diarrhoea, measured microbiome effects, the neurotoxicity dose-duration relationship, verbatim dosing, feline cautions, and stewardship-aligned alternatives.
Read →Famotidine in Dogs and Cats: A Clinical Reference
Famotidine works, modestly and briefly. A practising clinician's reference on where it sits versus omeprazole, the tachyphylaxis data in dogs and cats, the indications the evidence does not support, and when a PPI or nothing at all is the better call.
Read →Metoclopramide in Dogs and Cats: Antiemetic and Prokinetic Guide
A clinical reference on metoclopramide for dogs and cats: mechanism as a central D2 antiemetic and peripheral 5-HT4 prokinetic, verbatim intermittent and CRI dosing, indications for reflux and ileus, contraindications, adverse effects, and where it fits versus maropitant and ondansetron.
Read →Mirtazapine in Cats: Appetite Stimulant, Antiemetic & Dosing (Mirataz)
Clinical reference on mirtazapine for feline inappetence: the FDA-approved Mirataz transdermal dose, the Quimby-corrected extralabel oral regimen, CKD adjustment, efficacy data, adverse effects, serotonin-syndrome interactions, monitoring, and capromorelin as an alternative.
Read →Ondansetron in Dogs and Cats: A Clinical Reference for Vomiting and Nausea
A practicing-clinician reference on ondansetron for dogs and cats: mechanism, indications, oral and IV dosing, the low-oral-bioavailability problem, how it compares with maropitant and metoclopramide, adverse effects, and the efficacy evidence.
Read →Omeprazole and Gastroprotectants in Dogs: ACVIM Consensus, Overprescription Evidence, and Drug Interactions
Evidence-based review for DVMs: the 2018 ACVIM consensus reshaped omeprazole prescribing, yet a 265-vet survey shows persistent overprescription; long-term use raises gastrin without cobalamin change, and the feline clopidogrel interaction is PK-real but PD-limited.
Read →Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence
Evidence-based review of maropitant (Cerenia) for vomiting in dogs and cats — canine motion sickness, feline CKD, dexmedetomidine-induced emesis comparators, and the emerging visceral-analgesia role — with NK1 mechanism and FDA label facts.
Read →Capromorelin (Entyce & Elura) for Appetite Stimulation: Evidence and Clinical Use in Dogs and Cats
The clinician's evidence hub for capromorelin — the first ghrelin (GHS-R1a) receptor agonist appetite stimulant. Covers Entyce dosing and canine field-study efficacy, the Elura feline CKD pivotal RCT (+6.81% body-weight treatment effect), comparators, adverse effects, and cardiac/glycemic precautions.
Read →